Historical Royalty Revenue
Reported Net Sales Revenue by Product ($ in 000’s)
| Avastin | Q1 |
Q2 |
Q3 |
Q4 |
Total |
| 2010 |
1,586,093 |
1,596,892 |
|
|
3,182,984 |
| 2009 |
1,345,487 |
1,295,536 |
1,439,730 |
1,514,053 |
5,594,806 |
| 2008 |
980,715 |
1,084,930 |
1,180,427 |
1,239,382 |
4,485,454 |
| 2007 |
678,068 |
746,587 |
797,013 |
875,084 |
3,096,752 |
| 2006 |
439,318 |
516,052 |
570,551 |
592,897 |
2,118,817 |
| Herceptin | Q1 |
Q2 |
Q3 |
Q4 |
Total |
| 2010 |
1,337,732 |
1,349,512 |
|
|
2,687,244 |
| 2009 |
1,210,268 |
1,133,993 |
1,226,435 |
1,278,626 |
4,849,323 |
| 2008 |
1,105,426 |
1,195,215 |
1,211,982 |
1,186,806 |
4,699,428 |
| 2007 |
891,761 |
949,556 |
979,602 |
1,015,033 |
3,835,952 |
| 2006 |
529,585 |
659,719 |
761,099 |
803,576 |
2,753,979 |
| Lucentis | Q1 |
Q2 |
Q3 |
Q4 |
Total |
| 2010 |
759,965 |
698,890 |
|
|
1,458,855 |
| 2009 |
462,103 |
469,736 |
555,296 |
615,212 |
2,102,347 |
| 2008 |
363,615 |
393,682 |
460,167 |
454,922 |
1,672,386 |
| 2007 |
224,820 |
219,579 |
299,995 |
322,300 |
1,066,695 |
| 2006 |
– |
– |
10,689 |
157,742 |
168,431 |
| Xolair | Q1 |
Q2 |
Q3 |
Q4 |
Total |
| 2010 |
240,904 |
225,878 |
|
|
466,781 |
| 2009 |
184,669 |
181,086 |
211,006 |
219,693 |
796,454 |
| 2008 |
137,875 |
169,521 |
177,179 |
183,753 |
668,329 |
| 2007 |
129,172 |
130,700 |
144,250 |
147,754 |
551,876 |
| 2006 |
95,241 |
99,354 |
112,608 |
118,002 |
425,204 |
| Raptiva | Q1 |
Q2 |
Q3 |
Q4 |
Total |
| 2010 |
– |
14,224 |
|
|
14,224 |
| 2009 |
62,653 |
21,526 |
1,502 |
– |
85,681 |
| 2008 |
55,541 |
57,601 |
66,992 |
65,216 |
245,349 |
| 2007 |
45,134 |
47,401 |
52,914 |
53,885 |
199,333 |
| 2006 |
32,672 |
35,458 |
39,610 |
41,353 |
149,093 |
| Synagis | Q1 |
Q2 |
Q3 |
Q4 |
Total |
| 2010 |
– |
– |
|
|
– |
| 2009 |
571,486 |
623,951 |
57,271 |
105,314 |
1,358,021 |
| 2008 |
542,283 |
574,207 |
80,930 |
141,696 |
1,339,116 |
| 2007 |
478,388 |
548,227 |
53,586 |
139,736 |
1,219,936 |
| 2006 |
472,362 |
489,634 |
30,185 |
124,629 |
1,116,811 |
| Tysabri |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
| 2010 |
293,047 |
287,925 |
|
|
580,972 |
| 2009 |
221,854 |
229,993 |
257,240 |
285,481 |
994,569 |
| 2008 |
129,430 |
163,076 |
200,783 |
233,070 |
726,359 |
| 2007 |
30,468 |
48,715 |
71,972 |
94,521 |
245,675 |
| 2006 |
– |
– |
– |
7,890 |
7,890 |
| Actemra |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
| 2010 |
52,908 |
62,511 |
|
|
115,420 |
| 2009 |
19,504 |
17,920 |
30,313 |
39,888 |
107,627 |
| 2008 |
1,452 |
1,377 |
5,981 |
12,305 |
21,116 |
| 2007 |
2,388 |
873 |
1,071 |
1,137 |
5,470 |
| 2006 |
– |
– |
– |
– |
– |
| Mylotarg |
Q1 |
Q2 |
Q3 |
Q4 |
Total |
| 2010 |
8,500 |
8,658 |
|
|
17,159 |
| 2009 |
8,367 |
8,406 |
8,813 |
8,654 |
34,240 |
| 2008 |
8,978 |
8,050 |
8,225 |
8,140 |
33,393 |
| 2007 |
7,879 |
8,202 |
8,345 |
7,878 |
32,304 |
| 2006 |
8,832 |
9,084 |
8,874 |
16,081 |
42,871 |